Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow BMY
Bristol Myers Squibb Company (BMY) Return on assets
Bristol Myers Squibb Company's return on assets over the twelve months to 30 June 2026 was 10.2%, up 2.5 percentage points from fiscal 2025 (7.72%). Over the past ten years it has ranged from −9.53% (fiscal 2024) to 14.4% (fiscal 2018); the current reading is higher than 73% of that period. That is above the Drug Manufacturers General industry median of 2.57% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 7.72% | 17.25 |
| FY2024 | −9.53% | (17.89) |
| FY2023 | 8.36% | 2.22 |
| FY2022 | 6.14% | 0.00 |
| FY2021 | 6.14% | 13.40 |
| FY2020 | −7.26% | (11.43) |
| FY2019 | 4.17% | (10.19) |
| FY2018 | 14.4% | 11.37 |
| FY2017 | 2.99% | (10.63) |
| FY2016 | 13.6% | 8.84 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| NVS Novartis AG compare | 11.3% |
| BMY Bristol Myers Squibb Company | 10.2% |
| AMGN Amgen Inc. compare | 9.53% |
| AZN AstraZeneca PLC compare | 9.15% |
| GSK GSK PLC Sponsored ADR compare | 8.01% |
| SNY Sanofi compare | 3.21% |
| PFE Pfizer Inc. compare | 2.13% |
| GILD Gilead Sciences, Inc. compare | −6.17% |
| Drug Manufacturers General industry median | 2.57% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on BMY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement